ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare ARS Pharmaceuticals to related businesses based on the strength of its profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.
Analyst Ratings
This is a summary of current ratings and price targets for ARS Pharmaceuticals and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| ARS Pharmaceuticals Competitors | 7798 | 13888 | 25778 | 1037 | 2.41 |
ARS Pharmaceuticals currently has a consensus target price of $23.33, suggesting a potential upside of 736.32%. As a group, “Pharmaceuticals” companies have a potential upside of 25.57%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than its peers.
Volatility and Risk
ARS Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals’ peers have a beta of -3.71, meaning that their average share price is 471% less volatile than the S&P 500.
Profitability
This table compares ARS Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ARS Pharmaceuticals | -163.64% | -318.81% | -69.34% |
| ARS Pharmaceuticals Competitors | -2,380.38% | -217.94% | -15.54% |
Institutional & Insider Ownership
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares ARS Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| ARS Pharmaceuticals | $84.28 million | -$171.30 million | -1.28 |
| ARS Pharmaceuticals Competitors | $3.56 billion | $3.19 billion | 555.10 |
ARS Pharmaceuticals’ peers have higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
ARS Pharmaceuticals beats its peers on 7 of the 13 factors compared.
ARS Pharmaceuticals Company Profile
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
